Literature DB >> 22154938

A reverse binding motif that contributes to specific protease inhibition by antibodies.

Eric L Schneider1, Melody S Lee, Aida Baharuddin, David H Goetz, Christopher J Farady, Mick Ward, Cheng-I Wang, Charles S Craik.   

Abstract

The type II transmembrane serine protease family consists of 18 closely related serine proteases that are implicated in multiple functions. To identify selective, inhibitory antibodies against one particular type II transmembrane serine protease, matriptase [MT-SP1 (membrane-type serine protease 1)], a phage display library was created with a natural repertoire of Fabs [fragment antigen binding (Fab)] from human naïve B cells. Fab A11 was identified with a 720 pM inhibition constant and high specificity for matriptase over other trypsin-fold serine proteases. A Trichoderma reesei system expressed A11 with a yield of ∼200 mg/L. The crystal structure of A11 in complex with matriptase has been determined and compared to the crystal structure of another antibody inhibitor (S4) in complex with matriptase. Previously discovered from a synthetic single-chain variable fragment library, S4 is also a highly selective and potent matriptase inhibitor. The crystal structures of the A11/matriptase and S4/matriptase complexes were solved to 2.1 Å and 1.5 Å, respectively. Although these antibodies, discovered from separate libraries, interact differently with the protease surface loops for their specificity, the structures reveal a similar novel mechanism of protease inhibition. Through the insertion of the H3 variable loop in a reverse orientation at the substrate-binding pocket, these antibodies bury a large surface area for potent inhibition and avoid proteolytic inactivation. This discovery highlights the critical role that the antibody scaffold plays in positioning loops to bind and inhibit protease function in a highly selective manner. Additionally, Fab A11 is a fully human antibody that specifically inhibits matriptase over other closely related proteases, suggesting that this approach could be useful for clinical applications.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154938      PMCID: PMC3268006          DOI: 10.1016/j.jmb.2011.11.036

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  48 in total

1.  Structural basis for the inhibition of caspase-3 by XIAP.

Authors:  S J Riedl; M Renatus; R Schwarzenbacher; Q Zhou; C Sun; S W Fesik; R C Liddington; G S Salvesen
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

2.  A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.

Authors:  H J de Haard; N van Neer; A Reurs; S E Hufton; R C Roovers; P Henderikx; A P de Bruïne; J W Arends; H R Hoogenboom
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

3.  Efficient anisotropic refinement of macromolecular structures using FFT.

Authors:  G N Murshudov; A A Vagin; A Lebedev; K S Wilson; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

4.  Pushing the boundaries of molecular replacement with maximum likelihood.

Authors:  R J Read
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-09-21

5.  Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates.

Authors:  T Takeuchi; J L Harris; W Huang; K W Yan; S R Coughlin; C S Craik
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

6.  Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue.

Authors:  T Takeuchi; M A Shuman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

7.  Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase.

Authors:  Rainer Friedrich; Pablo Fuentes-Prior; Edgar Ong; Gary Coombs; Michael Hunter; Ryan Oehler; Diane Pierson; Richard Gonzalez; Robert Huber; Wolfram Bode; Edwin L Madison
Journal:  J Biol Chem       Date:  2001-11-05       Impact factor: 5.157

8.  Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.

Authors:  H H Petersen; M Hansen; S L Schousboe; P A Andreasen
Journal:  Eur J Biochem       Date:  2001-08

Review 9.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

10.  Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Authors:  Michael D Oberst; Michael D Johnson; Robert B Dickson; Chen-Yong Lin; Baljit Singh; Moira Stewart; Alastair Williams; Awatif al-Nafussi; John F Smyth; Hani Gabra; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

View more
  24 in total

1.  Functional selection of protease inhibitory antibodies.

Authors:  Tyler Lopez; Zahid Mustafa; Chuan Chen; Ki Baek Lee; Aaron Ramirez; Chris Benitez; Xin Luo; Ru-Rong Ji; Xin Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-30       Impact factor: 11.205

2.  Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors.

Authors:  Trine Tamberg; Zebin Hong; Daphné De Schepper; Signe Skovbjerg; Daniel M Dupont; Lars Vitved; Christine R Schar; Karsten Skjoedt; Lotte K Vogel; Jan K Jensen
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

3.  Compact and modular multicolour fluorescence detector for droplet microfluidics.

Authors:  Russell H Cole; Niek de Lange; Zev J Gartner; Adam R Abate
Journal:  Lab Chip       Date:  2015-06-02       Impact factor: 6.799

4.  Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.

Authors:  Tyler Lopez; Dong Hyun Nam; Evan Kaihara; Zahid Mustafa; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2017-02-20       Impact factor: 4.530

5.  Accurate Structure Prediction of CDR H3 Loops Enabled by a Novel Structure-Based C-Terminal Constraint.

Authors:  Brian D Weitzner; Jeffrey J Gray
Journal:  J Immunol       Date:  2016-11-21       Impact factor: 5.422

Review 6.  Why recombinant antibodies - benefits and applications.

Authors:  Koli Basu; Evan M Green; Yifan Cheng; Charles S Craik
Journal:  Curr Opin Biotechnol       Date:  2019-03-05       Impact factor: 9.740

7.  Efficient Antibody Assembly in E. coli Periplasm by Disulfide Bond Folding Factor Co-expression and Culture Optimization.

Authors:  Carlos Rodriguez; Dong Hyun Nam; Evan Kruchowy; Xin Ge
Journal:  Appl Biochem Biotechnol       Date:  2017-05-10       Impact factor: 2.926

Review 8.  Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression.

Authors:  Nisha R Pawar; Marguerite S Buzza; Toni M Antalis
Journal:  Cancer Res       Date:  2019-01-04       Impact factor: 12.701

9.  Imaging a functional tumorigenic biomarker in the transformed epithelium.

Authors:  Aaron M LeBeau; Minhee Lee; Stephanie T Murphy; Byron C Hann; Robert S Warren; Romelyn Delos Santos; John Kurhanewicz; Samir M Hanash; Henry F VanBrocklin; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

10.  Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.

Authors:  Dong Hyun Nam; Carlos Rodriguez; Albert G Remacle; Alex Y Strongin; Xin Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.